SSG
BMRN icon

Summit Securities Group’s BioMarin Pharmaceuticals BMRN Stock Holding History

Summit Securities Group’s Portfolio BMRN Stock Details BMRN Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2019
Q3 		– Sell
-150
Closed -$1.28M – 340
2019
Q2 		$1.28M Buy
+150
New +$12.8K 0.15% 110

Other funds holding BMRN

Capital Research Global Investors
Capital Research Global Investors Los Angeles, California $645B AUM 30.41% 1-Year Est. Return
Primecap Management
Primecap Management Pasadena, California $127B AUM 44.11% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return
Dodge & Cox
Dodge & Cox San Francisco, California $182B AUM 14.68% 1-Year Est. Return
BBA
Baker Bros. Advisors New York $17.4B AUM 131.5% 1-Year Est. Return
ClearBridge Investments
ClearBridge Investments New York $115B AUM 24.78% 1-Year Est. Return
Janus Henderson Group
Janus Henderson Group London, United Kingdom $209B AUM 37.72% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return
Ameriprise
Ameriprise Minneapolis, Minnesota $432B AUM 30.22% 1-Year Est. Return

Summit Securities Group's BMRN Position: Q3 2019 in Review

Summit Securities Group sold out of BioMarin Pharmaceuticals (BMRN) in Q3 2019, closing a stake of 6,000 shares — an estimated $514K sold.

Summit Securities Group first reported a position in BMRN in Q2 2019 and held it in 1 quarter. The position peaked at $514K in Q2 2019. 436 funds tracked by Wall St. Rank hold BMRN as of Q3 2019.

  • Summit Securities Group reported no remaining BioMarin Pharmaceuticals position as of Q3 2019 after selling out during the quarter.
  • Summit Securities Group sold 6,000 BioMarin Pharmaceuticals shares in Q3 2019, an estimated $514K.
  • Summit Securities Group first reported a position in BioMarin Pharmaceuticals in Q2 2019 and held it in 1 quarter.
  • Summit Securities Group's BioMarin Pharmaceuticals position peaked at $514K in Q2 2019.
  • 436 funds tracked by Wall St. Rank held BioMarin Pharmaceuticals as of Q3 2019.

Based on Summit Securities Group's 13F filing for Q3 2019, filed 18 Oct 2019.